Preservative-Free Cysteamine Formulation for DTS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dysfunctional tear syndrome (DTS) focus on palliative measures rather than addressing the underlying cause, and existing cysteamine products are associated with side effects like stinging and superficial corneal erosion due to preservatives, which deter their use for DTS.
Innovation Solution
Administering cysteamine or its derivatives, potentially combined with MMP inhibitors, in a pharmaceutically acceptable composition to reduce symptoms of DTS, with dosages ranging from 0.01 to 2.0 mg/ml, and incorporating excipients like glycerol to alleviate symptoms effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cysteamine products with preservatives are used to treat DTS, then therapeutic effectiveness is improved, but side effects like stinging and superficial corneal erosion increase
Solution Approach 1:
The patent removes preservatives from the cysteamine ophthalmic composition, extracting the harmful component while retaining the therapeutic cysteamine active ingredient. This resolves the contradiction by eliminating the source of stinging and corneal erosion while maintaining the disease-treating capability of cysteamine.
Solution Approach 2:
The patent changes the formulation parameters of the cysteamine product by eliminating preservatives and adjusting the concentration to 0.01-2.0 mg/ml. This parameter change transforms the product from a preservative-containing formulation that causes side effects to a preservative-free formulation that maintains therapeutic effectiveness without stinging or corneal erosion.
2Ease of operation
If current palliative treatments are used for DTS, then symptom management is provided, but underlying cause is not addressed
Solution Approach 1:
Cysteamine acts as an intermediary substance that addresses the underlying oxidative stress and MMP activity causing DTS, rather than merely providing palliative symptom relief. It mediates between the root cause (oxidative damage) and the symptoms (dry eye, corneal erosion) by scavenging free radicals and inhibiting MMPs, thereby treating both the cause and symptoms simultaneously.
3Reliability
If cysteamine is administered at higher concentrations to improve therapeutic effect, then symptom reduction is enhanced, but risk of side effects increases
Solution Approach 1:
The patent optimizes the cysteamine concentration parameter to a specific range (0.01-2.0 mg/ml) that maximizes therapeutic effectiveness while minimizing side effects. This parameter optimization resolves the contradiction by identifying the optimal concentration window where high symptom relief is achieved without proportionally increasing the risk of stinging or corneal erosion.
Solution Approach 2:
The patent creates a composite ophthalmic composition containing cysteamine combined with other compatible ingredients in a preservative-free formulation. This composite approach allows the use of effective cysteamine concentrations while the overall composition formulation mitigates potential side effects through synergistic or protective interactions with other components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cysteamine products demonstrate therapeutic effectiveness in reducing symptoms of DTS by inhibiting MMP activity, improving ocular lubrication, and enhancing glutathione production, as evidenced by patient improvements in Likert scores and Schirmer tests, with reduced side effects when formulated without preservatives.
Implementation Method 1
cysteamine products demonstrate therapeutic effectiveness in reducing symptoms of DTS by inhibiting MMP activity
Implementation Method 2
enhancing glutathione production
Data Source
AI summary
Methods for treating or inhibiting dysfunctional tear syndrome (DTS) or symptoms associated therewith, and compositions for use in the methods.